504413-35-8

Usage

Uses

Used in Pharmaceutical and Medicinal Research:
N-(6-Bromoimidazo[1,2-a]pyridin-2-yl)-2,2,2-trifluoroacetamide serves as a valuable building block for the synthesis of potential drug candidates. Its trifluoroacetamide group and imidazo[1,2-a]pyridine ring system provide a versatile synthetic intermediate for the development of new pharmaceuticals and bioactive compounds.
Used in Chemical Synthesis:
In the field of chemical synthesis, N-(6-Bromoimidazo[1,2-a]pyridin-2-yl)-2,2,2-trifluoroacetamide can be utilized as a key intermediate for the preparation of various organic compounds. Its unique structure allows for further functionalization and modification, enabling the creation of a wide range of molecules with diverse properties and applications.
Used in Drug Design and Development:
N-(6-Bromoimidazo[1,2-a]pyridin-2-yl)-2,2,2-trifluoroacetamide plays a crucial role in drug design and development, particularly in the discovery of novel therapeutic agents. Its structural features can be exploited to design molecules with improved pharmacological properties, such as enhanced potency, selectivity, and bioavailability.
Used in Biochemical Research:
In biochemical research, N-(6-Bromoimidazo[1,2-a]pyridin-2-yl)-2,2,2-trifluoroacetamide can be employed as a tool compound to study the interactions between small molecules and biological targets. Its unique chemical properties may facilitate the elucidation of molecular mechanisms and the identification of potential therapeutic targets.
Used in Material Science:
Although not explicitly mentioned in the provided materials, the trifluoroacetamide group in N-(6-Bromoimidazo[1,2-a]pyridin-2-yl)-2,2,2-trifluoroacetamide may also find applications in material science. The introduction of trifluoroacetamide moieties could potentially influence the properties of various materials, such as polymers, coatings, or sensors, by imparting specific chemical or physical characteristics.

Upstream product

• 209971-49-3 2,2,2-trifluoro-N-(6-iodoimidazo[1,2-a]pyridin-2-yl)acetamide 
• 937014-94-3 (Z)-2-(5-bromo-2-(tosylimino)pyridin-1(2H)-yl)acetamide 
• 407-25-0 trifluoroacetic anhydride 
• 1005785-49-8 2-[5-bromo-2-{[(4-methylphenyl)sulfonyl]imino}pyridin-1(2H)-yl]acetamide 
• 207801-52-3 N-(5-bromopyridin-2-yl)-4-methylbenzenesulfonamide 
• 1072-97-5 5-bromo-2-pyridylamine 

Downstream Products

• 1162680-84-3 N-(6-bromoimidazo[1,2-a]pyridin-2-yl)acetamide 
• 947249-08-3 N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-a]pyridine-2-yl)acetamide 
• 1192831-93-8 N-{6-[3-(methylsulfonyl)phenyl]imidazo[1,2-a]pyridin-2-yl}acetamide 
• 1192832-27-1 6-[3-(methylsulfonyl)phenyl]imidazo[1,2-a]pyridin-2-amine 
• 1192831-91-6 N-(6-{3-[(ethylamino)sulfonyl]phenyl}imidazo[1,2-a]pyridin-2-yl)-2,2,2-trifluoroacetamide 
• 1192832-26-0 2,2,2-trifluoro-N-{6-[3-(methylsulfonyl)phenyl]imidazo[1,2-a]pyridin-2-yl}acetamide 
• 947248-52-4 6-bromoimidazole[1,2-a]pyridine-2-amine 

Relevant academic research and scientific papers

HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME

The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosis. Formula (I) i

HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF

The present disclosure provides heteroaryl compounds of formulas (I), (Ia) and (Ib), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosi

FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE

The invention relates to compounds of formula (I) for the regulation of phosphoinositides 3-kinases activity and related diseases.

Inhibitors of PI3 kinase

The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof, that inhibit phosphoinositide 3-kinase; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds.

FUSED BICYCLIC COMPOUNDS AND USE THEREOF AS PI3K INHIBITORS

The invention relates to compounds of formula (I), for the regulation of phosphoinositides 3-kinases activity and related diseases.

BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS

Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE

Phosphatidylinositol (PI) 3 kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceuticall

Regioselective synthesis of 3,6-disubstituted-2-aminoimidazo[1,2-a]pyridines

A convenient synthesis of 3,6-disubstituted-2-aminoimidazo[1,2-a]pyridines 3 is described. A halogen-metal exchange study on building block 1 showed that use of i-propyl magnesium chloride is most effective for chemoselective functionalization at position